Multiple Myeloma Coverage from Every Angle

Paul G. Richardson, MD, on Treatment Strategies for Newly Diagnosed Multiple Myeloma

Posted: Tuesday, December 15, 2020

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, reviews pivotal studies presented at the 2020 American Society of Hematology Annual Meeting & Exposition and discusses integrating early vs late transplant with drugs such as daratumumab, carfilzomib, and anti-CD38 monoclonal antibodies into an overall treatment strategy for patients with newly diagnosed multiple myeloma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.